8-K: Niagen Bioscience Soars on Strong Q3, Boosts 2025 Outlook

Niagen Bioscience reported robust third-quarter 2025 financial results with significant revenue and profit growth, alongside an increased full-year sales forecast.

Summary

• Net sales for the third quarter of 2025 increased 33% year-over-year to $34.0 million.
• Tru Niagen sales, a key product line, grew 44% to $26.0 million.
• Gross margin improved by 100 basis points to 64.5%.
• Net income surged to $4.6 million, up from $1.9 million in the prior year quarter, resulting in $0.06 earnings per share.
• Adjusted EBITDA, a non-GAAP measure, increased 120% to $6.4 million.
• Cash provided by operations for the nine months ended September 30, 2025, totaled $12.8 million, with the company ending the quarter with $64.3 million in cash and no debt.
• The full-year 2025 net sales outlook was reaffirmed and increased to 25% to 30% year-over-year growth (up from a previous range of 22% to 27%).
• Launched AboutNAD, a new digital platform for NAD+ research and healthy aging, in September 2025.
• Successfully challenged a competitor's false NAD+ product claims in September 2025, reinforcing the need for scientific evidence.
• Expanded nationwide distribution of pharmaceutical-grade Niagen Plus IV and injectable therapies to over 1,000 clinics in October 2025.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong financial results across key metrics, including significant revenue growth, improved profitability, and robust cash generation. The increased full-year outlook and strategic operational achievements further bolster a highly positive sentiment.

Positives

• Total net sales increased significantly by 33% to $34.0 million, demonstrating strong market demand.
• Tru Niagen sales, a core product, showed exceptional growth of 44% to $26.0 million.
• Gross margin improved by 100 basis points to 64.5%, indicating better cost management and product mix.
• Net income more than doubled to $4.6 million, reflecting enhanced profitability.
• Adjusted EBITDA saw a substantial 120% increase to $6.4 million, highlighting operational efficiency.
• Strong cash generation from operations, with $12.8 million year-to-date, and a healthy cash balance of $64.3 million with no debt.
• Increased full-year 2025 net sales outlook to 25%-30% growth, signaling confidence in continued momentum.
• Strategic launch of AboutNAD platform strengthens scientific leadership and digital infrastructure.
• Successful National Advertising Division challenge against a competitor reinforces the company's commitment to evidence-based claims and market integrity.
• Expanded distribution of Niagen Plus IV therapies to over 1,000 clinics, broadening access and market reach.

Negatives

• General and administrative expenses are now expected to increase to approximately $8.0 to $9.0 million for the full year (previously $7.0 to $8.0 million), driven by higher share-based compensation and the absence of a 2024 royalty expense reversal.

Risks

• Inflationary conditions and adverse economic conditions could impact financial performance.
• History of operating losses, though current results are positive, remains a historical risk factor.
• Ability to maintain and grow sales, marketing, and distribution capabilities is crucial for sustained growth.
• Changing consumer perceptions of products could affect demand.
• Reliance on a single or limited number of third-party suppliers poses supply chain risks.
• Risks associated with conducting business in China, including unanticipated developments.
• Challenges in securing adequate quantities of pharmaceutical-grade Niagen in a timely manner.
• Difficulty in obtaining appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities.
• Risk of not remaining on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list.
• Ability to maintain and enforce existing intellectual property and obtain new patents is vital for competitive advantage.
• Uncertainty whether the potential benefits of NRC can be further supported by future research.
• Further research and development and clinical trials may be unsuccessful or insufficient to meet regulatory standards.
• Challenges in enrolling sufficient numbers of subjects in clinical trials.
• Determinations made by the FDA and other governmental authorities could impact product approvals or market access.
• Economic and market instability, including as a result of tariffs or trade conflicts.
• Inability to raise capital to fund continuing operations or new product development is a general financial risk.

Future Outlook

The company reaffirmed and increased its full-year 2025 net sales growth outlook to between 25% to 30% year-over-year, driven by strong momentum in Tru Niagen and Niagen ingredients. Gross margin is expected to improve year-over-year from 61.8% in 2024 due to supply chain optimization and lower-cost inventory sales. Sales and marketing expenses are projected to increase in absolute dollars but decrease as a percentage of net sales, reflecting targeted brand investment and greater marketing efficiency. Research and development expenses are now expected to decrease as a percentage of net sales while increasing in absolute dollars. General and administrative expenses are anticipated to increase to approximately $8.0 to $9.0 million, primarily due to higher share-based compensation and investments for business growth, and the absence of a 2024 royalty expense reversal.

Management Comments

• "We delivered another strong performance with third quarter net sales of $34.0 million, up 33% year-over-year, and $4.6 million in net income."
• "Our results reflected the continued execution across the business, with sustained sales growth, margin expansion, and disciplined cost management."
• "The progress across both scientific leadership and commercial reach reinforces our confidence in the long-term fundamentals of our leadership in the NAD+ category."

Industry Context

Niagen Bioscience operates in the healthy aging and dietary supplement market, specifically focusing on NAD+ precursors. The launch of AboutNAD and the successful advertising challenge against a competitor highlight the company's strategy to solidify its scientific leadership and promote evidence-based claims in a growing, yet competitive, market. The expansion of Niagen Plus IV distribution indicates a move towards broader clinical integration, aligning with trends in personalized wellness and preventative health.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against global industry standards. The focus is on internal growth metrics and market leadership within the NAD+ category.

Legal Proceedings

• Successful National Advertising Division challenge against another entity making false claims about their NAD+ products, which found no human clinical evidence that the competitor's products elevate NAD+ levels in the body. This reinforces the importance of rigorous scientific substantiation for claims in the NAD+ market.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased outlook, and strategic growth initiatives, potentially leading to increased share value.
• Customers: Enhanced access to scientific information through AboutNAD platform and broader availability of Niagen Plus IV therapies.
• Employees: Continued investments in business growth and R&D may indicate job stability and potential for growth.
• Competitors: The successful advertising challenge sets a precedent for evidence-based claims in the NAD+ market, potentially impacting competitors making unsubstantiated claims.

Next Steps

• Continue to execute across the business to drive sustained sales growth, margin expansion, and disciplined cost management.
• Further strengthen scientific leadership and commercial reach in the NAD+ category.
• Continue investments in external research to support new product development and NAD precursor development.
• Strategic investments to drive brand awareness, and increase customer acquisition and retention while enhancing marketing efficiencies.

Key Dates

Recommendation

Niagen Bioscience delivered exceptional Q3 2025 results, significantly exceeding prior-year performance across revenue, net income, and Adjusted EBITDA. The company also raised its full-year net sales guidance, indicating strong confidence in continued growth. Strategic operational achievements, such as the AboutNAD platform launch and expanded Niagen Plus distribution, reinforce its market leadership and future potential. With a healthy cash balance and no debt, the company is well-positioned for sustained expansion. The only minor negative is a slight increase in G&A outlook, which is offset by overall strong performance and strategic investments. These factors collectively point to a compelling investment opportunity.

Keywords

Niagen Bioscience, NAGE, NAD+, Tru Niagen, Nicotinamide Riboside Chloride, Healthy Aging, Dietary Supplements, Biotechnology, Financial Results, Earnings, Q3 2025, EBITDA, Sales Growth, Gross Margin, Pharmaceutical-grade Niagen, AboutNAD, IV Therapy